Since HCC cell lines have highly heterogeneous UCP2 expression levels (Figure 1A), we next determined whether therapeutic targeting of UCP2 is a feasible option only in those instances when it is in abundance or inhibition of even smaller amounts as found in HLE cells has an impact on cell growth. This evidence concerns the gene UCP2 and hepatocellular carcinoma.